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INTRODUCTION
Gastrointestinal malignancies in children present challenging
management issues and are often suggestive of inherited suscept-
ibility to cancer. DNA mismatch repair (MMR) genes, MLH1,
MSH2,MSH6, and PMS2 maintain genome integrity by correcting
DNA replication errors [1]. Defective MMR causes microsatellite
instability (MSI) (errors in length of microsatellites or repeated
sequences of DNA), a hallmark of MMR deficiency. Germline
heterozygous mutations in MMR genes results in Lynch syndrome
or Hereditary Non-Polyposis Colorectal Cancer (HNPCC), an
autosomal dominant cancer susceptibility syndrome with increased
risk for developing colorectal and endometrial malignancies.
Within the last decade there has been mounting evidence for an
inherited cancer syndrome resulting from germline biallelic
mutations in MMR genes which has been alternately referred to
Gastrointestinal malignancies are extremely rare in the pediatric
population, and duodenal cancers represent an even more unusual
entity. Intestinal cancers in young adults and children have been
observed to be associated with functional deficiencies of the
mismatch repair (MMR) system causing a cancer-predisposition
syndrome.We report the case of a 16-year-old female with duodenal
adenocarcinoma and past history of medulloblastoma found to have
a novel germline bialleleic truncating mutation (c.[949C>T]þ
[949C>T]) of the PMS2 gene. Pediatr Blood Cancer 2009;53:116–
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as childhood cancer syndrome (CCS), MMR-deficiency syndrome
(MMR-D) and constitutional MMR deficiency (CMMR-D) [2–4].
This syndrome results from complete deficiency of MMR function
and differs from HNPCC in the tumor spectrum, age of onset and
presence of café-au-lait macules (CALM).
CASE
A 16-year-old female of Syrian descent, with multiple CALM
was diagnosed with a moderately differentiated adenocarcinoma
arising in the ampulla and invading the pancreas, with metastases
to 6/39 lymph nodes. She underwent a Whipple procedure and
received adjuvant radiation therapy along with continuous 5-FU (5-
fluoro-uracil) infusion for 6 weeks, followed by eight cycles of
modified FOLFOX 6 (85 mg/m2 of oxaliplatin and 400 mg/m2
Leucovorin, followed by 400 mg/m2 5-FU bolus and 2,400 mg/m2
5-FU infusion for 46 hr). At the conclusion of chemotherapy,
imaging showed a new 2 cm sigmoid mass. Laparoscopic sigmoid
resection revealed an adenoma.
Her past history is significant for medulloblastoma diagnosed
at age 8, treated with surgery and radiation. Family history is
significant for parental consanguinity (Fig. 1A) and diagnosis of
precursor T-cell acute lymphoblastic leukemia (ALL) in younger
brother (IV.3) at age 5, who died at age 6. The history of
consanguinity in siblings with medulloblastoma and leukemia had
prompted a cancer genetics consultation 7 years ago in IV.3, who
also had CALM (largest measuring 4.5 cm) and several dysmorphic
features. His workup included evaluation for mutations in MLH1
and MSH2 based on reports in the literature documenting
hematologic malignancies as a feature of MMR deficiency [5,6].
No mutations in MLH1 and MSH2 were identified and tissue was
insufficient for immunohistochemistry (IHC) and MSI analysis.
The second diagnosis of duodenal cancer in the patient (IV.1) led to
further suspicion of MMR-D, and genetic counseling, molecular
diagnostic workup and enrollment in an IRB-approved cancer
genetics registry was offered.
MOLECULAR ANALYSIS
Duodenal carcinoma tissue analysis demonstrated high degreeof
MSI in 10/10 markers tested and IHC demonstrated absent PMS2
expression in tumor and normal tissue, with intact expression of
MLH1, MSH2, and MSH6 [7]. Blood samples of IV.1 and her
parents were tested for PMS2mutations on a research protocol [8].
After initial identification of the mutation, confirmatory testing was
performed in research and clinical laboratories at the University of
Michigan. PMS2 exon 9 was amplified using PCR primers 50-
GGCTGGGAACATTTGTCATT-30 and 50-TGCCAATGGAACT-
TACCTGA-30, purified and genotyped by direct sequencing on an
ABI 3730 sequencer. DNA sequence analysis (GenBank RefSeq-
NM_000535.5) using Mutation Surveyor software, revealed a
unique cytosine to thymine transition at coding nucleotide position
949 (949C>T) in thePMS2 exon 9 resulting in a codon change from
glutamine to a premature stop codon at amino acid 317 (Q317X)
(Fig. 1C). Consistent with the expectation from a consanguineous
family, IV.1 was homozygous for the mutation and both parents
were heterozygous for the same mutant allele. Analysis of IV.3’s
normal and tumor tissuewas hindered due to poor tissue quality, but
clearly demonstrated at least onemutant allele. The family declined
genetic testing of the other siblings.
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 1. Autosomal recessive susceptibility to cancer in a consanguineous Syrian family due to a homozygous mutation of PMS2. A: Pedigree
showing medulloblastoma at age 8 and duodenal carcinoma at age 16 in IV.1 and Pre T-cell ALL at age 5 in IV.3, whose parents are first cousins.
B: Immunohistochemistry showing intact expression ofMHL1 (top) and absent expression of PMS2 (bottom).C: Sequencing chromatograms show
a heterozygousmutation of PMS2 949C>T (Q317X)within exon 9 in both parents (who are unaffected), and a homozygousmutation in the affected
16-year-old female. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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Duodenal cancers are extremely rare with median age of
diagnosis in the sixth decade of life. A systematic literature search
for early onset duodenal cancers revealed five other cases (Table I),
four of which had germline biallelic MMR mutations [8–12]. A
comprehensive literature review through PubMed revealed 50
families with germline biallelic MMR mutations (Supplemental
Tables I and II). The present case is cited in two other reviews [4,8],
and here we present the full clinical details of this case and review
the implications of a diagnosis of MMR-D.
MMR-D phenotype is seen in homozygotes or compound
heterozygotes and absence of a family history of cancer does not
diminish its likelihood. Biallelic mutations in PMS2 accounted for
majority of cases in families with MMR-D (25/50 families, 50%),
while MLH1 and MSH6 each accounted for 20% of families, and
MSH2 accounted for 10% of families. Onset of tumors is as early as
the first decade of life and the tumor spectrum primarily comprises
of gastrointestinal (colorectal and small intestinal tumors), brain
(glioblastoma, astrocytoma, medulloblastoma, PNET), and hema-
tological malignancies (ALL and non-Hodgkin lymphoma, T-cell
type). Colorectal cancers were reported in 37 individuals in 27/50
(54%) families (median age: 17 years); small intestinal cancers in 7
individuals in 5/50 (10%) families (median age: 17 years); brain
tumors in 40 individuals in 29/50 (58%) families (median age:
8 years) and hematolological malignancies in 29 individuals in 19/
50 (38%) families (median age: 5 years). Other malignancies
reportedwere: 5 cases of endometrial cancer (median age: 24 years),
one case of ureter/renal pelvis cancer at age 15, two cases of
rhabdomyosarcoma (ages 4 and 18), one case of Wilms tumor (age
4), one case of infantile myofibromatosis (age 1), one case of
neuroblastoma (age 13), one case of breast cancer (age 35), one case
of ovarian neuroectodermal tumor (age 21) and one case of sarcoma
(age 65). Thirty two of the 84 (34.2%) patients developed more than
one primary tumor. Survival data reported in 64 patients revealed
that 38 patients (59.3%) died of their disease at median age of
10 years.
Multiple CALM have been reported in 35/50 (70%) families,
with only one patient having a germline NF-1 mutation [13].
However, NF1 may be a mutational target of MMR-deficiency
[5,13,14]. Hypopigmentation, immunodeficiencies and autoim-
mune diseases have been reported with biallelic MSH6 mutations
[15–18]. CALM have not been reported in any heterozygous
carriers. Although the chromatogram of IV.3 suggests that he is
heterozygous, his phenotype is more consistent with homozygosity.
The pseudogenePMS2CL sequence corresponds to exons 9 and 11–
15 of thePMS2 gene [19]; andmay be amplified by primers used for
amplification of PMS2 exon 9. Therefore it is likely that IV.3’s
chromatogram illustrates sequence data from both PMS2 and
PMS2CL.
Patients with MMR-D and their families need heightened
surveillance and we have recommended National Comprehensive
Cancer Network practice guidelines for HNPCC/Lynch syndrome
for IV.1 and her parents with the addition of annual upper endoscopy
for IV.1. Since HNPCC or MMR-D cannot be excluded in the other
siblings (IV.2, IV.4) similar surveillancewas recommended for them
as well until further information can be gained. Therapeutically it is
important to develop chemotherapeutic agents that are relevant for
these cancers since several in vitro studies have shown resistance
of MMR-deficient cell lines to commonly used agents [20]. In
conclusion, this case documents a novel mutation of PMS2,
underscores the clinical traits of the pediatric cancer syndrome of
MMR-D, emphasizes the clinical value of genetic testing, and
highlights pediatric duodenal carcinoma as a sentinel cancer of
MMR-D.
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INTRODUCTION
Little progress has been made in the survival of children with
metastatic and refractory solid tumors [1]. Allogeneic hemato-
poietic stem cell transplantation (HSCT) has been proposed as a
potential curative alternative in patients with refractory malignan-
cies [2]. A possible graft-versus-tumor (GVT) effect has been
documented in children with metastatic and relapsed Ewing
sarcoma [3], neuroblastoma [4], melanoma [5], and hepatoblastoma
[6]. However, the immunological mechanisms that mediate the
GVT effect have not been elucidated. Early immune reconstitution
after a conditioning regimen is led by natural killer (NK) cells, and
for several weeks, they represent the only detectable lymphoid
population. NK cell alloreactivity in vitro may be predicted by the
lack of ligands for inhibitory killer immunoglobulin-like receptors
(KIRs) [7]. Inhibitory KIRs bind with four specificities for
polymorphic human leukocyte antigen (HLA) class I molecules.
NK cell reactivity may be further enhanced by a Th1 cytokine
environment and by T-cell lymphopenia [8,9].
To evaluate the potential of NK cell-mediated GVT effect and
its immunological mechanisms, we performed a pilot study of




The study involved three patients with metastatic solid
tumors that were refractory to chemotherapy (Table I). This
study was approved by the Ethical Committee of Hospital Niño
Jesús. Informed consent was obtained in accordance with the
Helsinki Declaration. HSCT was performed using parental CD3/
CD19 depleted G-CSF mobilized peripheral blood. Reduced-
intensity conditioning consisted of busulfan (4 mg/kg/day, 2 days),
fludarabine (30 mg/m2/day, 5 days), thiotepa (5 mg/kg/day, 2 days),
and methylprednisolone (4 mg/kg/day, 5 days). Methotrexate
(15 mg/m2/day, day þ1, and 10 mg/m2/day, days þ3 and þ6) and
cyclosporine (3 mg/kg/day, day1 until 1 month after the infusion)
were also administered. Immune reconstitution and hematopoietic
chimerism were assessed monthly after HSCT. Computed tomo-
graphy andmagnetic resonance imagingwere performed before and
3 months after HSCT.
HLA Typing and KIR Genotyping, Phenotyping,
and Cytotoxicity
HLA-C allotypes (C1 andC2) andHLA-B allotypes (Bw4) were
determined using high-resolution polymerase chain reaction-
Killer immunoglobulin-like receptors (KIRs) on natural killer cells
(NKs) recognize groups of human leukocyte antigen (HLA) class I
alleles. Cells without an inhibitory HLA ligand may trigger NK
activation. Reduced risk of relapse has been reported in malignant
hematologic diseases after haploidentical transplantation when HLA
ligands against the inhibitory KIRs present in the donor were absent
in the recipient. We performed haploidentical transplant in three
children with refractory solid tumors. Our results showed that
beneficial antitumor effects could be observed in the presence of
inhibitory KIR–HLA mismatch. These preliminary results suggest a
possible association between disease control and NK cell allor-
eactivity. Pediatr Blood Cancer 2009;53:120–124.
 2009 Wiley-Liss, Inc.
Key words: haploidentical stem cell transplantation; KIR-HLA mismatch; NK cells; pediatric solid tumors
——————
1Department of Pediatric Hematology and Oncology, Hospital Niño
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